Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia

Abstract

Imatinib, a tyrosine kinase inhibitor, is well known to cause hypopigmentation because of its inhibitory effect on melanocytes. Herewith we report a case of chronic myeloid leukemia who developed extensive hyperpigmentation following imatinib therapy.

Keywords

• Hyperpigmentation
• Imatinib
• leukemia